

FIG. 8. Effects of ER α -glucosidase inhibitors on the infection with HCVrv and HCVcc. (A) (Top) Production of HCVrv and VSV in the presence of Nn-DNJ (left) or DMJ (right). Huh7 cells infected with HCVrv and VSV at MOIs of 0.1 and 0.01, respectively, were treated with various concentrations of Nn-DNJ or DMJ. Seventy-two hours (HCVrv) or 24 h (VSV) postinfection, culture supernatants were collected and titrated on Huh7 cells by a focus-forming assay. The results shown are from three independent assays, with the error bars representing the standard deviations. (Bottom) Purified viruses generated in Huh7 cells treated with Nn-DNJ or DMJ were analyzed by immunoblotting with anti-E1 (BD1198) and anti-VSVG (ab34774) or Coomassie staining. (B) Focus formation of HCVrv and VSV in the presence of Nn-DNJ or DMJ. Huh7 cells were infected with HCVrv or VSV, treated with Nn-DNJ (10 μ M) or DMJ (2 mM) prior to an overlay of culture media containing 0.8% of methylcellulose, and stained with an anti-VSV N antibody after fixation at 72 h (HCVrv) and 24 h (VSV) postinfection. (C) (Top) Production of HCVcc in the presence of Nn-DNJ (left) or DMJ (right). Huh7.5.1 cells infected with HCVcc at an MOI of 0.01 were treated with various concentrations of Nn-DNJ or DMJ. Culture supernatants were collected and titrated by a quantitative core enzyme-linked immunosorbent assay at 96 h postinfection. (Bottom) Immunofluorescence assay of HCVcc infection in the presence of Nn-DNJ or DMJ. Huh7.5.1 cells were infected with HCVcc at

the trimming step of N-linked glycosylation, have been shown to prevent the interaction of CNX and/or CRT with the folding glycoproteins, and the production of many enveloped viruses is inhibited by these inhibitors (41). In this study, we found that infection with both HCVrv and HCVcc was inhibited in a dose-dependent manner by treatment with Nn-DNJ, which is an N-alkylated derivative of DNJ exhibiting a stronger effect than DNJ. HCV E1 and E2 proteins were shown to interact with CNX and CRT, and these interactions were inhibited by the treatment with ER α -glucosidase inhibitors (12). One possible function of the HCV p7 protein, the formation of ion channels, has also been shown to be inhibited by the treatment with long-alkyl-chain iminosugar derivatives (50). Recently, it was reported that HCV-LPs produced in the presence of ER α -glucosidase inhibitors incorporated unprocessed, triglycosylated N-glycans and misfolded E1 and E2 proteins and lost their ability to bind hepatoma cell lines (11). Our results demonstrate that the modification of E1 and E2 proteins in the glycosylation steps in the ER is required to confer infectivity to HCVrv and HCVcc. The presence of E1 and E2 proteins on the surrogate viruses and HCVcc possessing high-mannose glycans indicate that these viruses are not released through the *trans*-Golgi network. In the case of West Nile virus, mature particles propagated in mammalian cells possess complex types of carbohydrates, in contrast to those generated in insect cells, which have high-mannose glycans (16). We still do not know the exact nature of modifications of the mature envelope proteins on authentic HCV particles. Further studies of the relationship between the modification of HCV envelope proteins and their infectivity are needed to clarify the life cycle of HCV. The neutralizing activity of antibodies against HCV have been assessed in the past using HCVpv (10, 43), HCVpp (3, 33, 42), and HCVcc (63, 65), as well as by the inhibition of binding of purified E2 protein to hCD81 (24, 53) and of HCV-LP to target cells (59). Sera from patients chronically infected with HCV and experimentally infected chimpanzees were shown to specifically neutralize HCVpp infection (3, 33, 42). In the present study, sera from patients infected with genotype 1b of HCV and anti-E2 monoclonal antibodies exhibited high levels of neutralization activity against infection with both HCVpv and HCVrv bearing HCV envelope proteins of genotypes 1a and 1b. One of the characteristics of HCV infection is the establishment of a persistent infection. Therefore, the high prevalence of neutralizing antibodies to the surrogate viruses and HCVcc suggests that HCV particles exhibiting similar phenotypes to surrogate viruses and HCVcc would be easily eliminated by neutralizing antibodies and thus not be able to participate in the establishment of a persistent infection. Recently, it was reported that HCV escapes from neutralizing antibody and T-cell responses by the continuous generation of escape

an MOI of 0.01, treated with 10 μ M of Nn-DNJ or 2 mM of DMJ prior to an overlay of culture media containing 0.8% of methylcellulose, and stained with an anti-NSSA antibody and Alexa 488-conjugated secondary antibody after fixation at 96 h postinfection. Cell nuclei were stained by Hoechst 33258. Pictures were taken using a fluorescence microscope by double exposure of the same fields with filters for Alexa 488 or Hoechst 33258.

variants during chronic infection (51, 62). However, it was demonstrated that viral clearance in acute HCV infection was not correlated with the presence of neutralizing antibodies against HCVpp (33, 42), and 75% of HCVpp bearing HCV envelope proteins of various genotypes are not infectious (29). Therefore, it is reasonable to speculate that HCV particles exhibiting characteristics similar to those of the surrogate viruses are produced in large numbers and act as decoys in HCV patients, eliciting strong neutralizing antibodies against the viruses, and that a small portion of HCV particles exhibiting characteristics different from those of the surrogate viruses may participate in the establishment of persistent infection by escaping from the host immune surveillance system. The authenticity of the surrogate virus systems for the study of HCV infection remains controversial, and further studies are needed to clarify their profiles.

In conclusion, we generated replication-incompetent HCVpv and replication-competent HCVrv possessing HCV envelope proteins as novel surrogate models for the study of HCV. HCVpv and HCVrv were shown to have infection mechanisms similar to those of HCVpp and HCVcc. HCVrv has the following advantages compared to HCVcc: (i) infectious particles bearing HCV envelope proteins of various genotypes are capable of generating in various cell lines or primary cells, in contrast to the strict restriction of generating the infectious HCVcc in the Huh7-derived cell lines; (ii) isolation of escape mutants carrying mutations in the envelope proteins under various pressures may be easily obtained due to the higher replication efficiency than that of HCVcc; and (iii) *in vivo* investigation of the HCV envelope proteins for entry using humanized mice with human Hc and for immunogenicity for a future vaccine development are possible. Therefore, replication-competent HCVrv established in this study may provide valuable tools not only for understanding the entry mechanisms of HCV in a manner that is cell type and species dependent but also for developing novel therapeutics and vaccines.

ACKNOWLEDGMENTS

We thank H. Murase for secretarial work and T. Ohtsubaki for excellent technical assistance. We also thank F. Cosset and F. Chisari for provision of the HCVpp system and Huh7.5.1 cells.

This research was supported in part by grants-in-aid from the Ministry of Health, Labor, and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; and the 21st Century Center of Excellence Program of Japan and by the Foundation for Biomedical Research and Innovation, Japan. H.T. was supported by research fellowships of the Japan Society for the Promotion of Science for Young Scientists.

REFERENCES

- Agnello, V., G. Abel, M. Elfahal, G. B. Knight, and Q. X. Zhang. 1999. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA* **96**:12766-12771.
- Barth, H., C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A. Kinoshita-Toyoda, T. Toida, T. H. Van Kuppevelt, E. Depla, F. Von Weizsacker, H. E. Blum, and T. F. Baumert. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. *J. Biol. Chem.* **278**:41003-41012.
- Bartosch, B., J. Bukh, J. C. Meunier, C. Granier, R. E. Engle, W. C. Blackwelder, S. U. Emerson, F. L. Cosset, and R. H. Purcell. 2003. *In vitro* assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. *Proc. Natl. Acad. Sci. USA* **100**:14199-14204.
- Bartosch, B., and F. L. Cosset. 2006. Cell entry of hepatitis C virus. *Virology* **348**:1-12.
- Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *J. Exp. Med.* **197**:633-642.
- Bartosch, B., A. Vitelli, C. Granier, C. Goujon, J. Dubuisson, S. Pascale, E. Scarselli, R. Cortese, A. Nicosia, and F. L. Cosset. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. *J. Biol. Chem.* **278**:41624-41630.
- Baumert, T. F., S. Ito, D. T. Wong, and T. J. Liang. 1998. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. *J. Virol.* **72**:3827-3836.
- Blanchard, E., S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C. Wychowski, and Y. Rouille. 2006. Hepatitis C virus entry depends on clathrin-mediated endocytosis. *J. Virol.* **80**:6964-6972.
- Buonocore, L., K. J. Blight, C. M. Rice, and J. K. Rose. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. *J. Virol.* **76**:6865-6872.
- Burioni, R., Y. Matsura, N. Mancini, H. Tani, T. Miyamura, P. E. Varaldo, and M. Clementi. 2002. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. *J. Virol.* **76**:1175-11779.
- Chapel, C., C. Garcia, P. Roingeard, N. Zitzmann, J. Dubuisson, R. A. Dwek, C. Trepo, F. Zoulim, and D. Durantel. 2006. Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. *J. Gen. Virol.* **87**:861-871.
- Choukai, A., S. Ung, C. Wychowski, and J. Dubuisson. 1998. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. *J. Virol.* **72**:3851-3858.
- Clayton, R. F., A. Owsianka, J. Aitken, S. Graham, D. Bhella, and A. H. Patel. 2002. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. *J. Virol.* **76**:7672-7682.
- Cormier, E. G., F. Tsamis, F. Kajumo, R. J. Durso, J. P. Gardner, and T. Dragic. 2004. CD81 is an entry coreceptor for hepatitis C virus. *Proc. Natl. Acad. Sci. USA* **101**:7270-7274.
- Courageot, M. P., M. P. Frenkiel, C. D. Dos Santos, V. Deubel, and P. Despres. 2000. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virus morphogenesis in the endoplasmic reticulum. *J. Virol.* **74**:564-572.
- Davis, C. W., H. Y. Nguyen, S. L. Hanna, M. D. Sanchez, R. W. Doms, and T. C. Pierson. 2006. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. *J. Virol.* **80**:1290-1301.
- Dubuisson, J. 2000. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. *Curr. Top. Microbiol. Immunol.* **242**:135-148.
- Evans, M. J., T. von Hahn, D. M. Tschernie, A. J. Syder, M. Panis, B. Wolk, T. Hatzioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* **446**:801-805.
- Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. *Proc. Natl. Acad. Sci. USA* **83**:8122-8126.
- Garbutt, M., R. Liebscher, V. Wahl-Jensen, S. Jones, P. Moller, R. Wagner, V. Volkov, H. D. Klenk, H. Feldmann, and U. Stroher. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. *J. Virol.* **78**:5458-5465.
- Gardner, J. P., R. J. Durso, R. R. Arrigale, G. P. Donovan, P. J. Maddon, T. Dragic, and W. C. Olson. 2003. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. *Proc. Natl. Acad. Sci. USA* **100**:4498-4503.
- Hamamoto, I., Y. Nishimura, T. Okamoto, H. Aizaki, M. Liu, Y. Mori, T. Abe, T. Suzuki, M. M. Lai, T. Miyamura, K. Moriishi, and Y. Matsuura. 2005. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J. Virol.* **79**:13473-13482.
- Hsu, M., J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C. M. Rice, and J. A. McKeating. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proc. Natl. Acad. Sci. USA* **100**:7271-7276.
- Ishii, K., D. Rosa, Y. Watanabe, T. Katayama, H. Harada, C. Wyatt, K. Kiyosawa, H. Aizaki, Y. Matsuura, M. Houghton, S. Abrignani, and T. Miyamura. 1998. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. *Hepatology* **28**:1117-1120.
- Jeetendra, E., K. Ghosh, D. Odell, J. Li, H. P. Ghosh, and M. A. Whitt. 2003. The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. *J. Virol.* **77**:12807-12818.
- Kanda, T., A. Basu, R. Steele, T. Wakita, J. S. Rysse, R. Ray, and R. B. Ray. 2006. Generation of infectious hepatitis C virus in immortalized human hepatocytes. *J. Virol.* **80**:4633-4639.
- Lagging, L. M., K. Meyer, R. J. Owens, and R. Ray. 1998. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. *J. Virol.* **72**:3539-3546.
- Lavillette, D., Y. Morice, G. Germanidis, P. Donot, A. Soulier, E. Pagkalos, G. Sakellariou, L. Intraor, B. Bartosch, J. M. Pawlotsky, and F. L. Cosset.

2005. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. *J. Virol.* **79**:6023-6034.
29. Lavillette, D., A. W. Tarr, C. Voisset, P. Donot, B. Bartosch, C. Bain, A. H. Patel, J. Dubuisson, J. K. Ball, and F. L. Cosset. 2005. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. *Hepatology* **41**:265-274.
30. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. *Proc. Natl. Acad. Sci. USA* **92**:4477-4481.
31. Lichty, B. D., A. T. Power, D. F. Stojdl, and J. C. Bell. 2004. Vesicular stomatitis virus: re-inventing the bullet. *Trends Mol. Med.* **10**:210-216.
32. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. *Science* **309**:623-626.
33. Lagvinoff, C., M. E. Major, D. Oldach, S. Heyward, A. Talai, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, and J. A. McKeating. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. *Proc. Natl. Acad. Sci. USA* **101**:10149-10154.
34. Lozach, P. Y., H. Lortat-Jacob, A. De Lacroix de Lavalette, I. Staropoli, S. Foug, A. Amara, C. Houles, F. Fieschi, O. Schwartz, J. L. Virelizier, F. Arenzana-Seisdedos, and R. Altmeyer. 2003. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. *J. Biol. Chem.* **278**:20358-20366.
35. Majid, A. M., H. Ezelle, S. Shah, and G. N. Barber. 2006. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. *J. Virol.* **80**:6993-7008.
36. Major, M. E., B. Rehmann, and S. M. Feinstone. 2001. Hepatitis C viruses, p. 1127-1162. *In* D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), *Fields virology*, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
37. Matsuo, E., H. Tani, C. K. Lim, Y. Komoda, T. Okamoto, H. Miyamoto, K. Morishi, S. Yagi, A. H. Patel, T. Miyamura, and Y. Matsuura. 2006. Characterization of HCV-like particles produced in a human hepatoma cell line by a recombinant baculovirus. *Biochem. Biophys. Res. Commun.* **340**:200-208.
38. Matsuura, Y., T. Suzuki, R. Suzuki, M. Sato, H. Aizaki, I. Saito, and T. Miyamura. 1994. Processing of E1 and E2 glycoproteins of hepatitis C virus expressed in mammalian and insect cells. *Virology* **205**:141-150.
39. Matsuura, Y., H. Tani, K. Suzuki, T. Kimura-Someya, R. Suzuki, H. Aizaki, K. Ishii, K. Morishi, C. S. Robison, M. A. Whitt, and T. Miyamura. 2001. Characterization of pseudotype VSV possessing HCV envelope proteins. *Virology* **286**:263-275.
40. Meerens, L., C. Bertaux, and T. Dragic. 2006. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. *J. Virol.* **80**:11571-11578.
41. Mehta, A., N. Zitzmann, P. M. Rudd, T. M. Block, and R. A. Dwek. 1998. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. *FEBS Lett.* **430**:17-22.
42. Meunier, J. C., R. E. Engle, K. Faulk, M. Zhao, B. Bartosch, H. Alter, S. U. Emerson, F. L. Cosset, R. H. Purcell, and J. Bukh. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. *Proc. Natl. Acad. Sci. USA* **102**:4560-4565.
43. Meyer, K., A. Basu, C. T. Przysocki, L. M. Lagging, A. M. Di Bisceglie, A. J. Conley, and R. Ray. 2002. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. *J. Virol.* **76**:2150-2158.
44. Morishi, K., and Y. Matsuura. 2003. Mechanisms of hepatitis C virus infection. *Antivir. Chem. Chemother.* **14**:285-297.
45. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**:193-199.
46. Ogino, M., H. Ebihara, B. H. Lee, K. Araki, A. Lundkvist, Y. Kawaoka, K. Yoshimatsu, and J. Arikawa. 2003. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. *Clin. Diagn. Lab. Immunol.* **10**:154-160.
47. Okamoto, T., Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K. Morishi, and Y. Matsuura. 2006. Hepatitis C virus RNA replication is regulated by FKBPs and Hsp90. *EMBO J.* **25**:5015-5025.
48. Op De Beeck, A., C. Voisset, B. Bartosch, Y. Ciczora, L. Cocquerel, Z. Keck, S. Foug, F. L. Cosset, and J. Dubuisson. 2004. Characterization of functional hepatitis C virus envelope glycoproteins. *J. Virol.* **78**:2994-3002.
49. Owsianka, A., A. W. Tarr, V. S. Juttla, D. Lavillette, B. Bartosch, F. L. Cosset, J. K. Ball, and A. H. Patel. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. *J. Virol.* **79**:11095-11104.
50. Pavlovic, D., D. C. Neville, O. Argaud, B. Blumberg, R. A. Dwek, W. B. Fischer, and N. Zitzmann. 2003. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. *Proc. Natl. Acad. Sci. USA* **100**:6104-6108.
51. Pestka, J. M., M. B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch, F. L. Cosset, A. H. Patel, H. Meisel, J. Baumert, S. Viazov, K. Rispeter, H. E. Blum, M. Roggendorf, and T. F. Baumert. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc. Natl. Acad. Sci. USA* **104**:6025-6030.
52. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of hepatitis C virus to CD81. *Science* **282**:938-941.
53. Rosa, D., S. Campagnoli, C. Moretto, E. Guenzi, L. Cousens, M. Chin, C. Dong, A. J. Weiner, J. Y. Lau, Q. L. Choo, D. Chien, P. Pileri, M. Houghton, and S. Abrignani. 1996. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. *Proc. Natl. Acad. Sci. USA* **93**:1759-1763.
54. Rose, J. K., L. Buonocore, and M. A. Whitt. 1991. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. *BioTechniques* **10**:520-525.
55. Sandrin, V., P. Boulanger, F. Penin, C. Granier, F. L. Cosset, and B. Bartosch. 2005. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. *J. Gen. Virol.* **86**:3189-3199.
56. Sandrin, V., D. Muriaux, J. L. Darlix, and F. L. Cosset. 2004. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. *J. Virol.* **78**:7153-7164.
57. Scarselli, E., H. Ansuini, R. Corino, R. M. Roccasacca, S. Acali, G. Filocamo, C. Traboni, A. Nicossia, R. Cortese, and A. Vitelli. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO J.* **21**:5017-5025.
58. Schneider-Schaulies, J. 2000. Cellular receptors for viruses: links to tropism and pathogenesis. *J. Gen. Virol.* **81**:1413-1429.
59. Steinmann, D., H. Barth, B. Gissler, P. Schurmann, M. I. Adah, J. T. Gerlach, G. R. Pape, E. Depla, D. Jacobs, G. Maertens, A. H. Patel, G. Inchauspe, T. J. Liang, H. E. Blum, and T. F. Baumert. 2004. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. *J. Virol.* **78**:9030-9040.
60. Tamura, K., A. Oue, A. Tanaka, N. Shimizu, H. Takagi, N. Kato, A. Morikawa, and H. Hoshino. 2005. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. *Microbes Infect.* **7**:29-40.
61. Tschernig, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating, and C. M. Rice. 2006. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. *J. Virol.* **80**:1734-1741.
62. von Hahn, T., J. C. Yoon, H. Alter, C. M. Rice, B. Rehmann, P. Balfe, and J. A. McKeating. 2007. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. *Gastroenterology* **132**:667-678.
63. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* **11**:791-796.
64. Wu, S. F., C. J. Lee, C. L. Liao, R. A. Dwek, N. Zitzmann, and Y. L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. *J. Virol.* **76**:3596-3604.
65. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc. Natl. Acad. Sci. USA* **103**:2310-2315.
66. Yu, M. Y., B. Bartosch, P. Zhang, Z. P. Guo, P. M. Renzi, L. M. Shen, C. Granier, S. M. Feinstone, F. L. Cosset, and R. H. Purcell. 2004. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. *Proc. Natl. Acad. Sci. USA* **101**:7705-7710.
67. Zhang, J., G. Randall, A. Higginbottom, P. Monk, C. M. Rice, and J. A. McKeating. 2004. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. *J. Virol.* **78**:1448-1455.
68. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. USA* **102**:9294-9299.
69. Zhong, J., P. Gastaminza, J. Chung, Z. Stamataki, M. Isogawa, G. Cheng, J. A. McKeating, and F. V. Chisari. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. *J. Virol.* **80**:11082-11093.

Enhanced TLR-mediated NF-IL6-dependent gene expression by Trib1 deficiency

Masahiro Yamamoto,^{1,3} Satoshi Uematsu,¹ Toru Okamoto,² Yoshiharu Matsuura,² Shintaro Sato,⁴ Himanshu Kumar,¹ Takashi Satoh,^{1,4} Tatsuya Saitoh,¹ Kiyoshi Takeda,^{3,5} Ken J. Ishii,⁴ Osamu Takeuchi,^{1,4} Taro Kawai,^{1,4} and Shizuo Akira^{1,4}

¹Department of Host Defense and ²Department of Molecular Virology, Research Institute for Microbial Diseases and ³Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan

⁴Exploratory Research for Advanced Technology, Japan Science and Technology Corporation, Suita, Osaka, 565-0871, Japan

⁵Department of Embryonic and Genetic Engineering, Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan

Toll-like receptors (TLRs) recognize a variety of microbial components and mediate downstream signal transduction pathways that culminate in the activation of nuclear factor κ B (NF- κ B) and mitogen-activated protein (MAP) kinases. Trib1 is reportedly involved in the regulation of NF- κ B and MAP kinases, as well as gene expression *in vitro*. To clarify the physiological function of Trib1 in TLR-mediated responses, we generated Trib1-deficient mice by gene targeting. Microarray analysis showed that Trib1-deficient macrophages exhibited a dysregulated expression pattern of lipopolysaccharide-inducible genes, whereas TLR-mediated activation of MAP kinases and NF- κ B was normal. Trib1 was found to associate with NF-IL6 (also known as CCAAT/enhancer-binding protein β). NF-IL6-deficient cells showed opposite phenotypes to those in Trib1-deficient cells in terms of TLR-mediated responses. Moreover, overexpression of Trib1 inhibited NF-IL6-dependent gene expression by down-regulating NF-IL6 protein expression. In contrast, Trib1-deficient cells exhibited augmented NF-IL6 DNA-binding activities with increased amounts of NF-IL6 proteins. These results demonstrate that Trib1 is a negative regulator of NF-IL6 protein expression and modulates NF-IL6-dependent gene expression in TLR-mediated signaling.

Downloaded from www.jem.org on August 30, 2007

CORRESPONDENCE

Shizuo Akira:
sakira@biken.osaka-u.ac.jp

Abbreviations used: 24p3, lipocalin-2; BLP, bacterial lipoprotein; C/EBP, CCAAT/enhancer-binding protein; Jnk, c-Jun N-terminal kinase; MAL P-2, macrophage-activating lipopeptide-2; MAP, mitogen-activated protein; mPGES, prostaglandin E synthase; TLR, Toll-like receptor.

Innate immunity is promptly activated after the invasion of microbes through recognition of pathogen-associated molecular patterns by pattern-recognition receptors, including Toll-like receptors (TLRs) (1). The recognition of microbial components by TLRs effectively stimulates host immune responses such as proinflammatory cytokine production, cellular proliferation, and up-regulation of co-stimulatory molecules, accompanied by the activation of NF- κ B and mitogen-activated protein (MAP) kinases (2, 3). Although the inhibitory protein I κ B family members sequester NF- κ B in the cytoplasm of unstimulated cells, TLR-dependent I κ B phosphorylation by the I κ B kinase complex and degradation by the ubiquitin-proteasome pathway permit translocation of NF- κ B to the nucleus (4). MAP kinases such as c-Jun N-terminal kinase (Jnk) and p38 are also rapidly phosphorylated

and activated by upstream kinases in response to TLR stimulation (5). Moreover, TLR-mediated activity of NF- κ B and MAP kinases is shown to be regulated at multiple steps regarding the strength and the duration of the activation (6).

Recent extensive experiments have identified a variety of modulators that have positive and negative effects on the activation of NF- κ B and MAP kinases, including a family of serine/threonine kinase-like proteins called Trib (7). Trib consists of three family members: Trib1 (also known as c8fw, GIG2, or SKIP1), Trib2 (also known as c5fw), and Trib3 (also known as NIPK, SINK, or SKIP3) (7–12). Trib3 has been shown to interact with the p65 subunit of NF- κ B and to inhibit NF- κ B-dependent gene expression *in vitro* (11). In terms of MAP kinases, Trib1, Trib2, and Trib3 reportedly bind to Jnk and p38, and affect the activity of MAP kinases and IL-8 production in response to PMA or

The online version of this article contains supplemental material.

TLR ligands/IL-1 (12). However, whether Trib family members regulate TLR-mediated signaling pathways under physiological conditions is still unknown.

In this study, we generated Trib1-deficient mice by gene targeting and analyzed TLR-mediated responses. Although the activation of NF- κ B and MAP kinases in response to LPS was comparable between wild-type and Trib1-deficient cells, microarray analysis revealed that a subset of LPS-inducible genes was dysregulated in Trib1-deficient cells. Subsequent yeast two-hybrid analysis identified the CCAAT/enhancer-binding protein (C/EBP) family member NF-IL6 (also known as C/EBP β) as a binding partner of Trib1, and phenotypes found in NF-IL6-deficient cells were opposite to those observed in Trib1-deficient cells. Moreover, overexpression of Trib1 inhibited NF-IL6-mediated gene expression and reduced amounts of NF-IL6 proteins. Inversely, NF-IL6 DNA-binding activity and LPS-inducible NF-IL6-target gene expression were up-regulated in Trib1-deficient cells, in which amounts of NF-IL6 proteins were increased. These results demonstrate that Trib1 plays an important role in NF-IL6-dependent gene expression in the TLR-mediated signaling pathways.

RESULTS

Comprehensive gene expression analysis in Trib1-deficient macrophages

To assess the physiological function of Trib1 in TLR-mediated immune responses, we performed a microarray analysis to compare gene expression profiles between wild-type and Trib1-deficient macrophages in response to LPS (Fig. 1 A and Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20070183/DC1>). Out of 45,102 transcripts, we first defined the genes induced more than twofold after LPS stimulation in wild-type cells as "LPS-inducible genes" and identified 790 of them (Table S1). We next compared the LPS-inducible genes in wild-type and Trib1-deficient macrophages after LPS stimulation and found 59, 703, and 28 genes as up-regulated, similarly expressed, and down-regulated in Trib1-deficient cells, respectively (Table S1).

Among the up-regulated genes, several were subsequently tested by Northern blotting to confirm the accuracy. LPS-induced expression of prostaglandin E synthase (mPGES), lipocalin-2 (24p3), arginase type II, and plasminogen activator inhibitor type II, which were highly up-regulated in the microarray analysis (Table S1), was indeed enhanced in Trib1-deficient macrophages (Fig. 1 B). Furthermore, in contrast to proinflammatory cytokines such as TNF- α and IL-6, which were similarly expressed between wild-type and Trib1-deficient cells in response not only to LPS but also to other TLR ligands, IL-12 p40 was down-regulated in Trib1-deficient cells compared with wild-type cells (Fig. 1 C; Fig. S2, A-C, available at <http://www.jem.org/cgi/content/full/jem.20070183/DC1>; and Table S1). Thus, the comprehensive microarray analysis revealed that a subset of LPS-inducible genes is dysregulated in Trib1-deficient cells.

Previous *in vitro* studies demonstrate that human Trib family members modulate activation of MAP kinases and




Figure 1. Dysregulation of a subset of LPS-inducible genes in Trib1-deficient cells. (A) Summary of DNA chip microarray analysis. 790 LPS-inducible genes were divided into up-regulated (yellow), similarly expressed (pink), and down-regulated (blue) groups, with the indicated amounts of each. (B) Peritoneal macrophages from wild-type or Trib1-deficient mice were stimulated with 10 ng/ml LPS for the indicated periods. Total RNA (10 μ g) was extracted and subjected to Northern blot analysis for the expression of the indicated probes. (C) Peritoneal macrophages from wild-type and Trib1-deficient mice were cultured with the indicated concentrations of LPS in the presence of 30 ng/ml IFN- γ for 24 h. Concentrations of IL-12 p40 in the culture supernatants were measured by ELISA. Indicated values are means \pm SD of triplicates. Data are representative of three (B) or two (C) independent experiments. N.D., not detected.

NF- κ B (7–12). Both wild-type and Trib1-deficient cells showed similar levels and time courses of phosphorylation of p38, Jnk and extracellular signal-regulated kinase, and I κ B α degradation (Fig. S2 D), indicating that the dysregulated

expression of LPS-inducible genes in Trib1-deficient cells might be independent of activation of NF- κ B and MAP kinases.

Interaction of Trib1 with NF-IL6

To explore signaling aspects of Trib1 deficiency other than NF- κ B and MAP kinases, we performed a yeast-two-hybrid screen with the full length of human Trib1 as bait to identify a binding partner of Trib1 and identified several clones as being positive. Sequence analysis subsequently revealed that three clones encoded the N-terminal portion of a member of the C/EBP NF-IL6 (unpublished data). We initially tested the interaction of Trib1 and NF-IL6 in yeasts. AH109 cells were transformed with a plasmid encoding the full length of Trib1 together with a plasmid encoding the N-terminal portion of NF-IL6 obtained by the screening (Fig. 2 A). We next examined the interaction in mammalian cells using immunoprecipitation experiments. HEK293 cells were transiently transfected with a plasmid encoding the full length of mouse Trib1 together with a plasmid encoding the full length of mouse NF-IL6. Myc-tagged NF-IL6 was coimmunoprecipitated

with Flag-Trib1 (Fig. 2 B), showing the interaction of Trib1 and NF-IL6 in mammalian cells.

TLR-mediated immune responses in NF-IL6-deficient macrophages

An *in vitro* study showing the interaction of Trib1 and NF-IL6 prompted us to examine the TLR-mediated immune responses in NF-IL6-deficient cells, because LPS-induced expression of mPGES is shown to depend on NF-IL6 (13). We initially analyzed the expression pattern of genes affected by the loss of Trib1 in NF-IL6-deficient macrophages by Northern blotting. LPS-induced expression of 24p3, plasminogen activator inhibitor type II, and arginase type II, as well as mPGES, was profoundly defective in NF-IL6-deficient cells (Fig. 2 C). We next tested IL-12 p40 production by ELISA. As previously reported, IL-12 p40 production by LPS stimulation was increased in a dose-dependent fashion in NF-IL6-deficient cells compared with control cells (Fig. 2 D) (14). In addition, the production in response to bacterial lipoprotein (BLP), macrophage-activating lipopeptide-2 (MALP-2), or CpG DNA was also augmented in




Figure 2. Association of Trib1 with NF-IL6 and TLR-mediated responses in NF-IL6-deficient macrophages. (A) Plasmids expressing human Trib1 fused to the GAL4 DNA-binding domain or an empty vector were cotransfected with a plasmid expressing NF-IL6 fused to GAL4 trans-activation domain or an empty vector. Interactions were detected by the ability of cells to grow on medium lacking tryptophan, leucine, and histidine (-L-W-H). The growth of cells on a plate lacking tryptophan and leucine (-L-W) is indicative of the efficiency of the transfection. (B) Lysates of HEK293 cells transiently cotransfected with 2 μ g of Flag-tagged Trib1 and/or 2 μ g Myc-tagged NF-IL6 expression vectors were immunoprecipitated with the indicated antibodies. (C) Peritoneal macrophages from wild-type or NF-IL6-deficient mice were stimulated with 10 ng/ml LPS for the indicated periods. Total RNA (10 μ g) was extracted and subjected to Northern blot analysis for expression of the indicated probes. (D and E) Peritoneal macrophages from wild-type and NF-IL6-deficient mice were cultured with the indicated concentrations of LPS (D) or with 100 ng/ml BLP, 30 ng/ml MALP-2, or 1 μ M CpG DNA (E) in the presence of 30 ng/ml IFN- γ for 24 h. Concentrations of IL-12 p40 in the culture supernatants were measured by ELISA. Indicated values are means \pm SD of triplicates. Data are representative of three (B) and two (C-E) separate experiments. N.D., not detected.

NF-IL6-deficient cells (Fig. 2E). Together, compared with Trib1-deficient cells, converse phenotypes in terms of TLR-mediated immune responses are observed in NF-IL6-deficient cells.

Inhibition of NF-IL6 by Trib1 overexpression

To test whether Trib1 down-regulates NF-IL6-dependent activation, HEK293 cells were transfected with an NF-IL6-dependent luciferase reporter plasmid together with NF-IL6 and various amounts of Trib1 expression vectors (Fig. 3A). NF-IL6-mediated luciferase activity was diminished by co-expression of Trib1 in a dose-dependent manner. Moreover, RAW264.7 macrophage cells overexpressing Trib1 exhibited reduced expression of mPGES and 24p3 in response to LPS (Fig. S3A, available at <http://www.jem.org/cgi/content/full/jem.20070183/DC1>). We next tested NF-IL6 DNA-binding activity by EMSA and observed less NF-IL6 DNA-binding activity in HEK293 cells coexpressing NF-IL6 and Trib1 than in ones transfected with the NF-IL6 vector alone (Fig. 3B), presumably accounting for the down-regulation of the NF-IL6-dependent gene expression by Trib1. We then examined the effect of Trib1 on the amounts of NF-IL6 proteins by Western blotting. Although the diminution of NF-IL6 by Trib1 was marginal when excess amounts of NF-IL6 were expressed, we found that the transient expression of lower levels of NF-IL6, together with Trib1, resulted in a reduction of NF-IL6 in HEK293 cells (Fig. 3C). Also, endogenous levels of NF-IL6 proteins in RAW264.7 cells overexpressing Trib1 were markedly less than those in control cells (Fig. 3D). These results demonstrated that overproduction of Trib1 might negatively regulate NF-IL6 activity in vitro.

Up-regulation of NF-IL6 in Trib1-deficient cells

We next attempted to check the in vivo status of NF-IL6 in Trib1-deficient cells by comparing the NF-IL6 DNA-binding activity in Trib1-deficient macrophages with that in wild-type cells by EMSA. Although LPS-induced NF- κ B-DNA complex formation in Trib1-deficient cells was similarly observed, Trib1-deficient cells exhibited elevated levels of C/EBP-DNA complex formation compared with wild-type cells (Fig. 4A). We further examined whether the C/EBP-DNA complex in Trib1-deficient cells contained NF-IL6 by supershift assay. Addition of anti-NF-IL6 antibody into the C/EBP-DNA complex yielded more supershifted bands in Trib1-deficient cells than in wild-type cells (Fig. 4B). In addition, the C/EBP-DNA complex was not shifted by the addition of anti-C/EBP δ (also known as NF-IL6 β) antibody (Fig. S4A, available at <http://www.jem.org/cgi/content/full/jem.20070183/DC1>), suggesting that NF-IL6 DNA-binding activity is augmented in Trib1-deficient cells. We then examined the amounts of NF-IL6 proteins by Western blotting (Fig. 4C). Compared with wild-type cells, Trib1-deficient cells showed increased levels of NF-IL6 proteins. Finally, we examined NF-IL6 mRNA levels by Northern blotting and observed enhanced expression of NF-IL6 mRNA in Trib1-deficient cells (Fig. 4D), which is consistent with the autocrine induction of




Figure 3. Inhibition of NF-IL6 activity by Trib1 overexpression.

(A) HEK293 cells were transfected with an NF-IL6-dependent luciferase reporter together with either Trib1 and/or NF-IL6 expression plasmids. Luciferase activities were expressed as the fold increase over the background shown by lysates prepared from mock-transfected cells. Indicated values are means \pm SD of triplicates. (B) HEK293 cells were transfected with 0.1 μ g NF-IL6 expression vector together with 4 μ g Trib1 expression plasmids. Nuclear extracts were prepared, and C/EBP DNA-binding activity was determined by EMSA using a probe containing the NF-IL6 binding sequence from the mouse 24p3 gene. (C) Lysates of HEK293 cells transiently cotransfected with 2 μ g of Flag-tagged Trib1 alone or the indicated amounts of Myc-tagged NF-IL6 expression vectors were immunoblotted with anti-Myc or -Flag for detection of NF-IL6 or Trib1, respectively. (E) RAW 264.7 cells stably transfected with either an empty vector or Flag-Trib1 were stimulated with 10 ng/ml LPS for the indicated periods. The cell lysates were immunoblotted with the indicated antibodies. A protein that cross-reacts with the antibody is indicated (*). Data are representative of three (A and C) and two (B and D), separate experiments.




Figure 4. Up-regulation of NF-IL6 activity in Trib1-deficient cells. (A) Peritoneal macrophages from wild-type or Trib1-deficient mice were stimulated with 10 ng/ml LPS for the indicated periods. Nuclear extracts were prepared, and C/EBP DNA-binding activity was determined by EMSA using a C/EBP consensus probe. (B) Nuclear extracts of wild-type and Trib1-deficient unstimulated macrophages were preincubated with anti-NF-IL6, followed by EMSA to determine the C/EBP DNA-binding activity. Super-shifted bands are indicated (*). (C) Peritoneal macrophages from wild-type or Trib1-deficient mice were stimulated with 10 ng/ml LPS for the indicated periods and lysed. The cell lysates were immunoblotted with the indicated antibodies. A protein that cross-reacts with the antibody is indicated (*). (D) Total RNA (10 μ g) from unstimulated peritoneal macrophages from wild-type or NF-IL6-deficient mice was extracted and subjected to Northern blot analysis for expression of the indicated probes. Data are representative of two (A and B) and three (C and D) separate experiments.

NF-IL6 mRNA in a previous study (15). Thus, Trib1 may negatively control amounts of NF-IL6 proteins, thereby affecting TLR-mediated NF-IL6-dependent gene induction.

DISCUSSION

In this study, we demonstrate by microarray analysis and biochemical studies that Trib1 is associated with NF-IL6 and negates NF-IL6-dependent gene expression by reducing the amounts of NF-IL6 proteins in the context of TLR-mediated responses.

Especially regarding IL-12 p40, although the microarray data showed an almost twofold reduction of the mRNA in Trib1-deficient cells (Table S1), the production was three to four times lower than that in wild-type cells (Fig. 1 C), suggesting translational control of IL-12 p40 by Trib1 in addition to the transcriptional regulation. Moreover, the transcription of the IL-12 p40 gene itself may be affected by not only the amount of NF-IL6 proteins but also the phosphorylation or the isoforms such as liver-enriched activator protein and liver-enriched inhibitory protein (16–18). The molecular mechanisms of how Trib1 deficiency affects IL-12 p40 production on the transcriptional or translational levels through NF-IL6 regulation need to be carefully studied in the future.

The name Trib is originally derived from the *Drosophila* mutant strain *tribbles*, in which the *Drosophila* tribbles protein negatively regulates the level of *Drosophila* C/EBP *slbo* protein and C/EBP-dependent developmental responses such as border cell migration in larvae (19–22). It is also of interest that Trib1-deficient female mice and *Drosophila* in adulthood are both infertile (unpublished data) (18). In mammals, other Trib family members such as Trib2 and Trib3 have recently been shown to be involved in C/EBP-dependent responses (23, 24). Mice transferred with bone marrow cells, in which Trib2 is retrovirally overexpressed, display acute myelogenous leukemia-like disease with reduced activities and amounts of C/EBP α (23). In addition, ectopic expression of Trib3 inhibits C/EBP-homologous protein-induced ER stress-mediated apoptosis (24). Thus, the function of tribbles to inhibit C/EBP activities by controlling the amounts appears to be conserved throughout evolution.

Given the up-regulation of the mRNA in Trib1-deficient cells (Fig. 4 D), the reduction of NF-IL6 in Trib1-overexpressing cells (Fig. 3 C), the auto-regulation of NF-IL6 by itself (15), and the degradation of C/EBP α by Trib2 (23) and *slbo* by tribbles (22), the loss of Trib1 might primarily result in impaired degradation of NF-IL6 and, subsequently, in excessive accumulation of NF-IL6 via the autoregulation in Trib1-deficient cells.

In this study, we focused on the involvement of Trib1 in TLR-mediated NF-IL6-dependent gene expression. However, given that the levels of NF-IL6 proteins were increased in Trib1-deficient cells, it is reasonable to propose that other non-TLR-related NF-IL6-dependent responses might be enhanced in Trib1-deficient mice. Moreover, Trib3 is also shown to be involved in insulin-mediated Akt/PKB activation in the liver by mechanisms apparently unrelated to C/EBP, suggesting that Trib family members possibly function in a C/EBP-independent fashion (25–27). Future studies using mice lacking other Trib family members, as well as Trib1, may help to unravel the nature of mammalian tribbles in wider points of view.

MATERIALS AND METHODS

Generation of Trib1-deficient mice. A genomic DNA containing the *Trib1* gene was isolated from the 129/SV mouse genomic library and characterized by restriction enzyme mapping and sequencing analysis. The gene encoding mouse Trib1 consists of three exons. The targeting vector was constructed by replacing a 0.4-kb fragment encoding the second exon of the

Trib1 gene with a neomycin resistance gene cassette (*neo*) (Fig. S1 A). The targeting vector was transfected into embryonic stem cells (E14.1), G418 and gancyclovir doubly resistant colonies were selected and screened by PCR and Southern blot analysis (Fig. S1 B). Homologous recombinants were microinjected into C57BL/6 female mice, and heterozygous F1 progenies were intercrossed to obtain *Trib1*^{-/-} mice. We interbred the heterozygous mice to produce offspring carrying a null mutation of the gene encoding *Trib1*. *Trib1*-deficient mice were born at the expected Mendelian ratio and showed a slight growth retardation with reduced body weight until 2–3 wk after birth (unpublished data). *Trib1*-deficient mice survived for >6 wk were analyzed in this study. To confirm the disruption of the gene encoding *Trib1*, we analyzed total RNA from wild-type and *Trib1*-deficient peritoneal macrophages by Northern blotting and found no transcripts for *Trib1* in *Trib1*-deficient cells (Fig. S1 C). All animal experiments were conducted with the approval of the Animal Research Committee of the Research Institute for Microbial Diseases at Osaka University.

Reagents, cells, and mice. LPS (a TLR4 ligand) from *Salmonella minnesota* Re 595 and anti-Flag were purchased from Sigma-Aldrich, BLP (TLR1/TLR2), MALP-2 (TLR2/TLR6), and CpG oligodeoxynucleotides (TLR9) were prepared as previously described (28). Antiphosphorylated extracellular signal-regulated kinase, Jnk, and p38 antibodies were purchased from Cell Signaling, Anti-NF-IL6 (C/EBP β), C/EBP β , actin, I κ B α , and Myc-probe were obtained from Santa Cruz Biotechnology, Inc. NF-IL6-deficient mice were as previously described (29). Epitope-tagged *Trib1* fragments were generated by PCR using cDNA from LPS-stimulated mouse peritoneal macrophages as the template and cloned into pcDNA3 expression vectors, according to the manufacturer's instructions (Invitrogen).

Measurement of proinflammatory cytokine concentrations. Peritoneal macrophages were collected from peritoneal cavities 96 h after thioglycollate injection and cultured in 96-well plates (10^6 cells per well) with the indicated concentrations of the indicated ligands for 24 h, as shown in the figures. Concentrations of TNF- α , IL-6, and IL-12 p40 in the culture supernatant were measured by ELISA, according to manufacturer's instructions (TNF- α and IL-12 p40, Genzyme; IL-6, R&D Systems).

Luciferase reporter assay. The NF-IL6-dependent reporter plasmids were constructed by inserting the promoter regions (-1200 to +53) of the mouse 24p3 gene amplified by PCR into the pGL3 reporter plasmid. The reporter plasmids were transiently cotransfected into HEK293 cells with the control *Renilla* luciferase expression vectors using a reagent (Lipofectamine 2000; Invitrogen). Luciferase activities of total cell lysates were measured using the Dual-Luciferase Reporter Assay System (Promega), as previously described (28).

Yeast two-hybrid analysis. Yeast two-hybrid screening was performed as described for the Matchmaker two-hybrid system 3 (CLONTECH Laboratories, Inc.). For construction of the bait plasmid, the full length of human *Trib1* was cloned in frame into the GAL4 DNA-binding domain of pGBKT7. Yeast strain AH109 was transformed with the bait plasmid plus the human lung Matchmaker cDNA library. After screening of 10^6 clones, positive clones were picked, and the pACT2 library plasmids were recovered from individual clones and expanded in *Escherichia coli*. The insert cDNA was sequenced and characterized with the BLAST program (National Center for Biotechnology Information).

Microarray analysis. Peritoneal macrophages from wild-type or *Trib1*-deficient mice were left untreated or were treated for 4 h with 10 ng/ml LPS in the presence of 30 ng/ml IFN- γ . The cDNA was synthesized and hybridized to Murine Genome 430 2.0 microarray chips (Affymetrix), according to the manufacturer's instructions. Hybridized chips were stained and washed and were scanned with a scanner (GeneArray; Affymetrix). Microarray Suite software (version 5.0; Affymetrix) was used for data analysis. Microarray data have been deposited in the Gene Expression Omnibus under accession no. GSE8788.

Western blot analysis and immunoprecipitation. Peritoneal macrophages were stimulated with the indicated ligands for the indicated periods, as shown in the figures. The cells were lysed in a lysis buffer (1% Nonidet P-40, 150 mM NaCl, 20 mM Tris-CI [pH 7.5], 5 mM EDTA) and a protease inhibitor cocktail (Roche). The cell lysates were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. For immunoprecipitation, cell lysates were precleared with protein G-sepharose (GE Healthcare) for 2 h and incubated with protein G-sepharose containing 1 μ g of the antibodies indicated in the figures for 12 h, with rotation at 4°C. The immunoprecipitates were washed four times with lysis buffer, eluted by boiling with Laemmli sample buffer, and subjected to Western blot analysis using the indicated antibodies, as previously described (28).

EMSA and supershift assay. 2×10^6 peritoneal macrophages were stimulated with the indicated stimulants for the indicated periods, as shown in the figures. 2×10^6 HEK293 cells were transfected with 0.1 μ g Myc-NF-IL6 and/or 4 μ g Flag-*Trib1* expression vectors. Nuclear extracts were purified from cells and incubated with a probe containing a consensus C/EBP DNA-binding sequence (5'-TGAGATTGGCAATCTGCA-3'; Fig. 4, A and B) or mouse 24p3 NF-IL6 binding sequence (sense, 5'-CTTCCTGTTGCTCAACCTTGCA-3'; antisense, 5'-TGCAAGTTGAGCAACAGGAA-3'; Fig. 3 B), electrophoresed, and visualized by autoradiography, as previously described (28, 30). When the supershift assay was performed, nuclear extracts were mixed with the supershift-grade antibodies indicated in the figures before the incubation with the probes for 1 h on ice.

Online supplemental material. Fig. S1 showed our strategy for the targeted disruption of the mouse *Trib1* gene. Fig. S2 showed the status of proinflammatory cytokine production in response to various TLR ligands and LPS-induced activation of MAP kinases and I κ B degradation. Fig. S3 showed decreased expression of NF-IL6-dependent gene in *Trib1*-overexpressing cells. Fig. S4 showed that the C/EBP-DNA complex in *Trib1*-deficient cells contained NF-IL6, but not C/EBP β . Table S1 provides a complete list of the LPS-inducible genes studied. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20070183/DC1>.

We thank M. Hashimoto for excellent secretarial assistance, and N. Okita, N. Iwami, N. Fukuda, and M. Morita for technical assistance.

This study was supported by the Special Coordination Funds, the Ministry of Education, Culture, Sports, Science and Technology, research fellowships from the Japan Society for the Promotion of Science for Young Scientists, the Uehara Memorial Foundation, the Naito Foundation, the Institute of Physical and Chemical Research Junior Research Associate program, and the National Institutes of Health (grant AI070167).

The authors have no conflicting financial interests.

Submitted: 24 January 2007

Accepted: 26 July 2007

REFERENCES

- Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. *Cell* 124:783–801.
- Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. *Nature* 430:257–263.
- Kopp, E., and R. Medzhitov. 2003. Recognition of microbial infection by Toll-like receptors. *Curr. Opin. Immunol.* 15:396–401.
- Hayden, M.S., and S. Ghosh. 2004. Signaling to NF- κ B. *Genes Dev.* 18:2195–2224.
- Zhang, Y.L., and C. Dong. 2005. MAP kinases in immune responses. *Cell. Mol. Immunol.* 2:20–27.
- Miggin, S.M., and I.A. O'Neill. 2006. New insights into the regulation of TLR signaling. *J. Leukoc. Biol.* 80:220–226.
- Hegedus, Z., A. Czibula, and E. Kiss-Toth. 2007. Tribbles: A family of kinase-like proteins with potent signalling regulatory function. *Cell. Signal.* 19:238–250.
- Kiss-Toth, E., S.M. Bagstaff, H.Y. Sung, V. Jozsa, C. Dempsey, J.C. Cantu, K.M. Osley, D.H. Wylie, T. Polgar, M. Harter et al. 2004.

- Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. *J. Biol. Chem.* 279:42703–42708.
9. Wilkin, F., N. Suarez-Huerta, B. Robaye, J. Peetermans, F. Libert, J.E. Dumont, and C. Maenhaut. 1997. Characterization of a phosphoprotein whose mRNA is regulated by the mitogenic pathways in dog thyroid cells. *Eur. J. Biochem.* 248:660–668.
 10. Mayumi-Matsuda, K., S. Kojima, H. Suzuki, and T. Sakata. 1999. Identification of a novel kinase-like gene induced during neuronal cell death. *Biochem. Biophys. Res. Commun.* 258:260–264.
 11. Wu, M., L.G. Xu, Z. Zhai, and H.B. Shu. 2003. SINK is a p65-interacting negative regulator of NF- κ B-dependent transcription. *J. Biol. Chem.* 278:27072–27079.
 12. Kris-Toth, E., D.H. Wyllie, K. Holland, L. Marsden, V. Jozsa, K.M. Osley, T. Polgar, E.E. Qvarnstrom, and S.K. Dowse. 2006. Functional mapping and identification of novel regulators for the Toll/Interleukin-1 signalling network by transcription expression cloning. *Cell. Signal.* 18:202–214.
 13. Uematsu, S., M. Matsumoto, K. Takeda, and S. Akira. 2002. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF- κ B pathway. *J. Immunol.* 168:5811–5816.
 14. Gorosni, B., D. Mantano, P. Marthyn, M. Righi, and V. Poli. 2002. C/EBP β gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. *J. Immunol.* 168:4055–4062.
 15. Ranjji, D.P., and P. Foka. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. *Biochem. J.* 365:561–575.
 16. Plevy, S.E., J.H. Gemberling, S. Hsu, A.J. Dorner, and S.T. Smale. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. *Mol. Cell. Biol.* 17:4572–4588.
 17. Zhu, C., K. Gagnidze, J.H. Gemberling, and S.E. Plevy. 2001. Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter. Demonstration of novel functional elements by a reductionist approach. *J. Biol. Chem.* 276:18519–18528.
 18. Bradley, M.N., L. Zhou, and S.T. Smale. 2003. C/EBP β regulation in lipopolysaccharide-stimulated macrophages. *Mol. Cell. Biol.* 23:4841–4858.
 19. Scher, T.C., and M. Leptin. 2000. Tribbles, a cell-cycle brake that coordinates proliferation and morphogenesis during *Drosophila* gastrulation. *Curr. Biol.* 10:623–629.
 20. Mata, J., S. Carado, A. Ephrussi, and P. Rorth. 2000. Tribbles coordinates mitosis and morphogenesis in *Drosophila* by regulating string/CDC25 proteolysis. *Cell.* 101:511–522.
 21. Groshans, J., and E. Wieschaus. 2000. A genetic link between morphogenesis and cell division during formation of the ventral furrow in *Drosophila*. *Cell.* 101:523–531.
 22. Rorth, P., K. Szabo, and G. Tesado. 2000. The level of C/EBP protein is critical for cell migration during *Drosophila* oogenesis and is tightly controlled by regulated degradation. *Mol. Cell.* 6:23–30.
 23. Keeshan, K., Y. He, B.J. Wouters, O. Shestova, L. Xu, H. Sai, C.G. Rodriguez, I. Maillard, J.W. Tobias, P. Valk, et al. 2006. Tribbles homolog 2 inactivates C/EBP α and causes acute myelogenous leukemia. *Cancer Cell.* 10:401–411.
 24. Ohoka, N., S. Yoshii, T. Hattori, K. Onozaki, and H. Hayashi. 2005. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. *EMBO J.* 24:1243–1255.
 25. Du, K., S. Herzig, R.N. Kulkarni, and M. Montminy. 2003. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. *Science* 300:1574–1577.
 26. Koo, S.H., H. Satoh, S. Herzig, C.H. Lee, S. Hedrick, R. Kulkarni, R.M. Evans, J. Olefsky, and M. Montminy. 2004. PGC-1 promotes insulin resistance in liver through PPAR- α -dependent induction of TRB3. *Nat. Med.* 10:530–534.
 27. Qi, L., J.E. Heredia, J.Y. Altarejos, R. Screaton, N. Goebel, S. Nussen, L.X. Macleod, C.W. Liew, R.N. Kulkarni, J. Bain, et al. 2006. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. *Science* 312:1763–1766.
 28. Yamamoto, M., T. Okamoto, K. Takeda, S. Sato, H. Sanjo, S. Uematsu, T. Satoh, N. Yamamoto, H. Sakurai, K.J. Ishii, et al. 2006. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. *Nat. Immunol.* 7:962–970.
 29. Tanaka, T., S. Akira, K. Yoshida, M. Umemoto, Y. Yoneda, N. Shirafuji, H. Fujiwara, S. Suetsugu, N. Yoshida, and T. Kishimoto. 1995. Targeted disruption of the NF- κ B gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. *Cell.* 80:353–361.
 30. Shen, F., Z. Hu, J. Goswami, and S.L. Gaffen. 2006. Identification of common transcriptional regulatory elements in interleukin-17 target genes. *J. Biol. Chem.* 281:24138–24148.

REVIEW



Host factors involved in the replication of hepatitis C virus

Kohji Moriishi and Yoshiharu Matsuura*

Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

SUMMARY

Hepatitis C virus (HCV) is the major causative agent of blood-borne hepatitis. The majority of HCV-infected individuals develop chronic hepatitis, which eventually progresses to liver cirrhosis, and hepatocellular carcinoma. Although the precise mechanisms of entry, replication, assembly, egress and pathogenesis of HCV are largely unknown, information about viral receptor candidates has accumulated by the development of pseudotype viruses and an *in vitro* replication system of the HCV JFH1 strain. Furthermore, the autonomous RNA replication system based on the artificial viral genome revealed that HCV replicates in the intracellular replication complex composed of viral and host proteins. Recently, an immunosuppressant, cyclosporin A and inhibitors for sphingolipid synthesis and chaperon were reported to inhibit the replication of HCV by counteracting the interplay between host and viral proteins. This review considers the current knowledge of the host proteins that participate in HCV replication and the possibility of developing novel therapeutics intervention for chronic hepatitis C. Copyright © 2007 John Wiley & Sons, Ltd.

Received: 22 March 2007; Accepted: 10 April 2007

INTRODUCTION

Hepatitis C, which is caused by infection with hepatitis C virus (HCV), is a serious form of chronic hepatitis with steatosis and cirrhosis, and eventually leads to hepatocellular carcinoma [1]. HCV is classified into a member of genus *Hepacivirus* of the family *Flaviviridae* [1]. Epidemiological study reveals that 170 million individuals worldwide are infected with HCV, mostly through blood-borne infection [2]. Introduction of combination therapy with interferon alpha and ribavirin improved therapeutic efficacy, but had no effect on half of the individuals infected with a high viral load of HCV genotype 1 [3,4]. Therefore, effective therapeutic measures are required for the treat-

ment of hepatitis C patients who are not responsive to chemotherapy. An HCV replicon system was established as a representative functional system composed of an antibiotic gene for selection and HCV genomic RNA for autonomous replication in the intracellular compartments around the endoplasmic reticulum (ER) [5]. Studies on HCV replication have used the replicon system, and small chemicals targeted to HCV proteins have been identified [6–10]. On the other hand, a pseudotype viral system based on the vesicular stomatitis virus and retrovirus has been developed to study the receptor determination and the entry mechanism [1]. Recently, an *in vitro* cell culture system for HCV of genotype 2a, which is highly sensitive to interferon therapy [11,12], has been developed [13–15]. However, a robust cell culture system for the HCV 1a and 1b genotypes, which are both the most prevalent genotypes in the world and resistant to interferon therapy, has not yet been successful.

HCV possesses a single positive strand RNA genome encoding a large polyprotein composed of approximately 3000 amino acid residues [1]. The polyprotein is cleaved by the viral proteases

*Corresponding author: Y. Matsuura, DVM, PhD, Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan.
E-mail: matsuura@biken.osaka-u.ac.jp

Abbreviations used

CaM, calmodulin binding domain; Dlh, Desert hedgehog; ER, endoplasmic reticulum; FBD, FK506-binding domain; FKBP, FK506-binding proteins; HCV, hepatitis C virus; Ihh, Indian hedgehog; MSP, major sperm protein; NS, nonstructural; ORPs, oxysterol-binding protein-related proteins; Ptc, Patched; Smo, Smoothened; Shh, Sonic hedgehog; VAMP, vesicle-associated membrane protein.

NS2 and NS3 and by host proteases including signal peptidase and signal peptide peptidase. Viral structural protein, capsid protein (core) and two envelope proteins (E1 and E2) occupy the N-terminal third of the polyprotein, while nonstructural (NS) proteins located in the remaining region. NS3, NS4A, NS4B, NS5A and NS5B are essentially required for autonomous replication in the replicon cells [5]. NS3 possesses the RNA helicase and protease activities [16,17], and NS4A fulfils anchoring NS3 on the intracellular membrane [18]. NS4B is a membrane protein modelling the ER membrane in order to make it suitable for efficient HCV viral replication [19]. NS5A is a phosphoprotein required for HCV replication [20], because adaptive mutations for efficient RNA replication in the HCV replicon were selectively introduced into the NS5A coding region [21]. NS5B is the active subunit of the replication complex known as an RNA-dependent RNA polymerase [22]. Recent reports suggest that several host proteins attend to the formation of the HCV replication complex [9,10,23,24]. In this review, we summarise the physiological and pathological functions of the host proteins that directly or indirectly participate in the replication of HCV.

IMMUNOPHILINS AND HSP90

The peptide bond *cis/trans* isomerases catalyse the conversion between *cis* and *trans* peptide bonds for

correct folding of the protein substrate, including peptidyl prolyl *cis/trans* isomerase (PPIase), such as the families of cyclophilins [25], FK506-binding proteins (FKBP) [26,27] and parvulins [28] and the secondary amide peptide bond *cis/trans* isomerase (APIase) [29]. Cyclophilin and FKBP are classified as immunophilins capable of binding to immunosuppressants cyclosporine and FK506, respectively [30]. The family members do not share a homologous domain with each other, based on their amino acid sequences, substrate specificities and inhibitor sensitivities. Recently, cyclophilin B and FKBP8 were shown to interact with NS5B and NS5A, respectively, and to regulate HCV replication [9,10], suggesting that the immunophilins are promising therapies for chronic hepatitis C (Figure 1).

Cyclophilin B

A study of the host gene related to resistance to retrovirus infection revealed that HIV capsid interacts with cyclophilin A [31], which is incorporated into viral particles, but its precise functions in the viral life cycle have not been elucidated yet. HIV particles lacking cyclophilin A exhibited no abnormality in virus packaging, reverse transcriptase activity or capsid stability [32]. However, in macaque cells, cyclophilin A modulates conformation of gag capsid protein to facilitate the interaction with TRIM5 α , a potent antiretroviral restriction factor and confers resistance to human




Figure 1. Structures of cyclophilin B and FKBP8. Cyclophilin B possesses a cyclophilin domain and a transmembrane region. FKBP8 has an FK506-binding domain (FBD), three sets of tricopeptide repeats (TPRs), a calmodulin-binding domain (CaM) and a transmembrane region (TM). Both proteins catalyse the conversion between *cis* and *trans* propyl peptide bonds for correct folding of protein substrate

retrovirus, which participates in the establishment of host range restriction [33,34].

Cyclophilin B, formerly called s-cyclophilin, is identified as a 20 kDa secreted neurotrophic factor for spinal cord cells of chick embryo [35], and it is secreted into human milk and blood [36,37]. Extracellular cyclophilin B enhances the retrotranslocation of prolactin into nucleus [38], is implicated in the presynaptic function by interacting with synaptin I, and impairs the correct folding of prion protein in the presence of cyclosporin A, leading to accumulation in aggresomes [39]. Therefore, cyclophilin B may regulate the correct folding and translocation of host proteins under extracellular and intracellular conditions, although its precise functions are still unknown.

Cyclosporin A and its derivatives capable of inhibiting cyclophilins were shown to inhibit HCV RNA replication and to be effective in the treatment of hepatitis C patients [9,40,41]. Inoue *et al.* [42] reported at the first time that cyclosporin A is effective for the treatment of hepatitis C patients. Cyclosporin derivatives lacking the ability to interact with cyclophilin lost their inhibitory effect on HCV replication [9]. Cyclophilin B was shown to specifically interact with NS5B, the HCV RNA-dependent RNA polymerase, around

the ER of the HCV replicon cells and to promote NS5B's association with the viral RNA [9]. Cyclosporin A was shown to disrupt interaction between NS5B and cyclophilin B [9] (Figure 2). Treatment with cyclosporin A and knockdown of cyclophilin B suppressed the replication of HCV, suggesting that cyclophilin B plays an important role in HCV genome replication by enhancing the interaction between NS5B and viral RNA [9].

FKBP8

HCV NS5A is an essential component of the viral replication complex, although NS5A's function has not been clarified yet. We screened the human fetal brain and liver libraries using a yeast two-hybrid system that employs HCV NS5A as bait and identified FKBP8 as an NS5A-binding partner [10] (Figure 2). An immunoprecipitation analysis revealed that NS5A bound to FKBP8 but not to FKBP52 or cyclophilin D, all three of which have homology to each other.

FKBP8 belongs to the FKBP family based on sequence similarity, but lacks the amino acid residues essential for either FK506 binding or PPIase activity [43]. Recent biochemical and enzymological studies indicate that FKBP8 has weak PPIase activity and low affinity to FK506 [44,45], suggest-




Figure 2. Interaction of HCV NS5A and NS5B proteins with immunophilins and Hsp90. Cyclophilin B interacts with NS5B. FKBP8 interacts with NS5A and Hsp90 through the different regions within TPR domains. Lys³⁰⁷ and Arg³¹¹ of the FKBP8 carboxylate clamp motif are required for binding to the MEEVD motif of Hsp90. Cyclosporin A inhibits interaction between cyclophilin B and NS5B. Geldanamycin is an inhibitor of the ATPase activity of Hsp90

ing that FK506 is unable to modulate FKBP8 function. Previously, FKBP8 was termed FKBP38 or FKBP α 38 (FKBP-related protein 38 kDa) from the deduced molecular weight of 38 kDa based on the fact that the incomplete amino acid sequence was missing the N-terminal part of the authentic FKBP8. The true transcription and translation initiation sites were identified in the upstream of the original start site in the genomic sequences [46]. The FKBP8 splicing variants of 44 and 46 kDa were detected in mouse but not in human, and the 45 kDa of human FKBP8 corresponds to the 44 kDa of murine protein [46].

The physiological function of FKBP8 is largely unknown, but is slightly elucidated from the data of genetically manipulated mice [47]. FKBP8 $^{-/-}$ mice exhibit a phenotype similar to that of mutant mice under the excessive activation of the Sonic hedgehog (Shh) protein, a secreted morphogen that regulates the patterning and growth of many tissues in the developing mouse embryo [47]. Human and mouse have three species of hedgehog proteins: Indian hedgehog (Ihh), Desert hedgehog (Dhh) and Shh [48,49]. Ihh and Dhh are predominantly expressed in bone and gonads, respectively, whereas Shh is ubiquitously expressed in many organs such as brain, liver and lungs. Shh is secreted as glycoprotein from the ventral midline of the spinal cord and is involved in the regulation of the genes related to the control of ventral fate in the spinal cord and forebrain [50,51]. Hedgehog protein generally binds to the receptor protein Patched (Ptc) and then inhibits the function of the membrane protein Smoothened (Smo) [52,53]. Smo activates the protein kinase A, which suppresses the transcription factor GLI protein by phosphorylation [54]. Phosphorylated GLI was inactivated by cleavage and acts as a transcriptional repressor against a full length of GLI in hedgehog signalling [54]. Hedgehog protein binds to the receptor Ptc and then inhibits Smo, leading to the accumulation of the full length of the GLI protein [55]. Deficiency in the murine Shh gene or knockouts of the genes required for Shh signal transduction abolished control over morphological formation [51,56]. On the other hand, excessive Shh signalling exhibited the opposite phenotype, including cells that inappropriately adopt ventral identities for dorsal identities [48,57]. FKBP8-deficient mice were reported to exhibit phenotypes similar to those of

mice expressing excessive Shh signalling, except that the FKBP8-deficient mice had no abnormalities of the limb pads, bronchial arches or somites [47]. Shh $^{-/-}$ and FKBP8 $^{-/-}$ double knockout embryos showed partial rescue of cyclopia and holoprosencephaly, but still showed limb outgrowth defect [47]. These results suggest that Shh signalling in the brain is overlapped with FKBP8-controlled signalling including phosphorylation and protein-protein interaction. Shirane *et al.* [58] suggest that FKBP8 is an inherent phosphatase inhibitor and retains Bcl-2 on mitochondrial membrane to inhibit apoptosis. However, there was no difference between wild-type and FKBP8-deficient mice with respect to apoptosis, suggesting that FKBP8 deficiency does not affect physiological apoptosis. FKBP8 may modulate a phosphatase such as calcineurin to enhance the phosphorylation required for suppression of Shh signalling.

Hsp90

Proteomics analysis reveals that FKBP8 forms a complex with Hsp90 to act as a co-chaperone [10]. Although both NS5A and Hsp90 bound to the TPR domain of FKBP8, interaction between NS5A and FKBP8 did not affect homomultimerisation of FKBP8 or complex formation with Hsp90. The amino acid residues of the carboxylate clump position in the TPR domain of FKBP8 grasp the C-terminal MEEVD motif of Hsp90. Mutations of the residues in the carboxylate clump of FKBP8 suppressed the interaction with Hsp90 but not that with NS5A, suggesting that FKBP8 interacts with NS5A and Hsp90 at different sites within the TPR domain. Knockdown of FKBP8 and treatment with geldanamycin, an ATPase inhibitor of Hsp90, downregulated HCV replication in HCV replicon cells. These data suggest that recruitment of Hsp90 to the replication complex through the interaction between FKBP8 and NS5A is crucial for the replication of HCV (Figure 2). It is also feasible to speculate that NS5A modulates the activity of unidentified phosphatases by the interaction with FKBP8 to facilitate the replication of HCV RNA. Although Hsp90 was shown to be involved in the cleavage between NS2 and NS3 [59], NS2 is not required for the replication of the HCV genome [5].

Hsp90 was suggested to be involved in the enzymatic activity and intracellular localisation of several viral enzymes, including polymerases. Hsp90 was shown to bind to a viral polymerase subunit

of influenza virus to facilitate the replication complex formation and the nuclear localisation of the viral polymerase subunit [60,61]. The DNA polymerase of herpes simplex virus type 1 required the chaperone activity of Hsp90 for the nuclear localisation of the polymerase [62]. Flock house virus utilises Hsp90 to assemble the complex of the RNA-dependent RNA polymerase on the intracellular membrane [63]. Knockdown and treatment with Hsp90 inhibitor revealed that Hsp90 activity is important for the rapid growth of negative strand RNA viruses [64]. Furthermore, Hsp90 was shown to be required for the activity of the hepatitis B reverse transcriptase [65,66]. Hsp90 generally requires the co-chaperone protein to acquire specificity to the substrate client. Therefore, Hsp90 and co-chaperones are crucial molecules required for the efficient replication of a broad range of viruses and are an ideal target for antivirals with broad spectra. Recently, Hsp90 inhibitors were shown to drastically impair the replication of poliovirus without any emergence of escape mutants [67].

Immunophilins and Hsp90 may be involved in HCV replication through the correct folding of the replication complex required for efficient enzymatic activity. In addition, cyclophilin B may also participate in the translocation of NS5B, as seen in the polymerase subunits of influenza virus, to facilitate binding to viral RNA. Elucidation of the HCV replication complex may lead to the development of new therapeutics for chronic hepatitis C.

VESICLE-ASSOCIATED MEMBRANE PROTEIN-ASSOCIATED PROTEINS

VAPs were originally identified as proteins that bind to vesicle-associated membrane protein (VAMP) in the nematode *Aplysia* and were designated as VAMP-associated protein 33 kDa (VAP-33) [68]. After that, one homologue and its splicing variant were identified as VAP-B and -C, respectively [69], and VAP-33 has been renamed VAP-A. Although VAP-A was suggested to be required for delivery of components into the presynaptic membrane of *Aplysia* ganglion [68,70], in mouse organs both VAP-A and -B localise in the intracellular membrane compartments, including ER, but not in the VAMP [68,71]. In addition, VAP-A, -B and -C are ubiquitously expressed in mammalian organs, such as heart, placenta, lung, liver, skeletal muscle and pancreas [72], suggesting that VAP

proteins possess have other functions besides neurotransmitter release [69,70,73].

VAP is a type II membrane protein composed of three functional domains: the N-terminal half of the protein, which is highly homologous with the nematode major sperm protein (MSP); the coiled-coil domain and the transmembrane domain. VAP-A shares 60% identity with VAP-B, while VAP-C is the splicing variant of VAP-B that lacks a transmembrane domain [69]. MSP was identified as one of the major proteins of the nematode sperm [74] and forms a microfilament required for amoeboid motility through the push-pull theory. MSPs form a subfilament by homodimerisation through the Ig-like domain and coiled coil around each other to form a filament. Several filaments are further assembled around each other to make a macrofiber [75,76]. The MSP-like domain was identified in several mammalian, avian, arthropod, plant and fungal proteins but not in protist proteins [77].

VAP-interacting proteins share the FFAT motif represented by the consensus amino acid sequence EFFDaxE as determined by a comparison of oxysterol-binding protein-related proteins (ORPs) [78]. However, both VAMP and tubulin are capable of binding to VAP proteins in an FFAT-independent manner [70,79–81]. In yeast, Opi1p is the transcriptional repressor of the INO1 gene, which encodes an inositol-1-phosphate synthase [72,82]. SCS2p is a yeast homologue of VAP and interacts with Opi1p through the FFAT motif to regulate the expression of the INO1 gene [78]. In mammals, ceramide is transported by the cargo protein CERT from ER to Golgi for the synthesis of sphingomyelin [83,84]. VAP-A and -B could anchor CERT via the FFAT motif to uptake ceramide by CERT in ER [85], suggesting that VAPs serve as anchors for the transporter of ceramide in mammalian cells rather than as a component of neurotransmitter release machinery.

VAP-A and -B were reported to be NS5A-binding host proteins by the screening of the human hepatoma cell line library using NS5A as bait in yeast [23,24]. GST pulldown and immunoprecipitation analyses revealed that NS5A and NS5B interact with human VAP-A and that the N-terminal MSP domain and the coiled-coil domain of VAP-A are responsible for the binding to NS5B and NS5A, respectively [24] (Figure 3). Several host kinases were shown to phosphorylate NS5A,




Figure 3. Interaction between HCV NS5A protein and VAPs. VAP-A and VAP-B make homo- and hetero-dimers with each other. The VAP dimer interacts with NS5A and NS5B through the coiled-coil domain and the MSP domain, respectively. VAP-A and VAP-B share 62.9 and 84.9% homology in total and in the MSP domain, respectively

and the hyperphosphorylation of NS5A abrogates the interaction with human VAP-A, which leads to the downregulation of HCV replication [20,86–88]. Adaptive mutation for an efficient replication of HCV RNA in the Huh7 cell line was associated with hypophosphorylation of NS5A, which enhances binding to VAP-A [20]. NS5A of HCV genotype 1a H77 strain was shown to be hyperphosphorylated in both yeast and replicon cells, and no interaction with VAP-A was detected in yeast, suggesting that hyperphosphorylation of NS5A may suppress HCV RNA replication through by counteracting binding to VAP-A [20]. However, we have demonstrated that NS5A of genotype 1a H77 strain is capable of binding not only to VAP-A but also to VAP-B at levels similar to that of genotype 1b in mammalian cells [23].

Several reports suggest that HCV replication takes place on the detergent-resistant membrane fraction [6,89,90]. NS4B is predominantly associated with a lipid-raft-like detergent-resistant fraction, and both NS5A and NS5B are co-localised in the similar fraction in the presence of NS4B [89].

VAP-A was also localised in the detergent-resistant fraction, suggesting that it plays an important role in HCV replication, because the dominant negative mutant of VAP-A suppressed the replication of HCV RNA [89]. VAP-B forms a homodimer and heterodimer with VAP-A, and knockdown of VAP-A or VAP-B led to a substantial suppression of HCV replication [23,91], suggesting that heterodimerisation of VAPs could regulate HCV replication (Figure 3). The host proteins possessing the FFAT motif are related to biosynthesis and translocation of lipid [81], whereas NS5A and NS5B do not have the typical FFAT motif. Although replication of HCV RNA did not affect lipid biosynthesis, lipid components are required to form the HCV replication complex as described below. VAPs might be involved in the transport of lipid components to the HCV replication complex through the interaction with NS5A and NS5B, resulting in the upregulation of HCV replication. VAP-B was shown to interact with Nir2 protein through the FFAT motif and to remodel the ER structure [92]. It can therefore be speculated that VAPs are asso-

ciated with remodelling of the HCV replication complex in the ER membrane through interaction with Nir2 protein.

HOST PROTEINS MODIFIED BY LIPID AND INVOLVED IN LIPID BIOSYNTHESIS

Lipid components are required for the assembly, budding and replication of several viruses [93–97]. Increases in saturated and monounsaturated fatty acids enhance HCV RNA replication, in contrast to suppression by polyunsaturated fatty acids [98], suggesting that enzymes associated with lipid biosynthesis are also involved in HCV replication. SREBP-1c regulates the transcription of acetyl-CoA carboxylase, fatty acid synthase and stearoyl-CoA desaturase, leading to the production of saturated and monounsaturated fatty acids and triglycerides [99]. Expression of HCV core protein induces the production of lipid droplets composed mainly of triglyceride [100]. Our recent study suggests that SREBP-1c was upregulated in the liver of transgenic mice expressing HCV core protein through the LXRA α /RXRA α -dependent pathway, which leads to the development of fatty liver [101]. The upregulation of SREBP-1c in the core transgenic mice was required for expression of PA28 γ , an HCV core-binding host protein involved in the activation of nuclear proteasome activity. Saturated or monounsaturated fatty acid

may be utilised for the formation of HCV replication complex with cholesterol and sphingolipid [98]. A lipophilic long-chain compound derived from microbial metabolites, an inhibitor of sphingolipid biosynthesis, was shown to inhibit HCV replication [6]. The HCV replication complex is shown to be localised in the lipid raft including sphingolipid [89,90,102]. Therefore, compounds disrupting sphingolipid biosynthesis may inhibit the replication of HCV through the modification of the lipid raft (Figure 4).

HCV replication was also disrupted with an inhibitor of geranylgeranyl transferase I but not with that of farnesyl transferase [103], suggesting that geranylgeranylation of viral or host protein regulates HCV replication efficiency [103]. Geranylgeranylate is an intermediate of the mevalonate pathway and is attached to various cellular proteins for anchoring to plasma or intracellular membrane [99]. Wang *et al.* [104] reported that geranylgeranylated FBL2 is required for the efficient replication of HCV genomic RNA. FBL2 had been identified as a structural homologue of Skp2, which interacts with Skp1 for S-phase entry and conserves the structural motif of F-box for Skp1 binding [105]. The immunoprecipitation analysis revealed that NS5A interacts with FBL2 [104]. The F-box motif is located in the N-terminus of FBL2, followed by 11 leucine-rich repeats [105]




Figure 4. Putative model of HCV replication complex composed of viral and host proteins

and the CAAX motif (CVIL), which is suggested to be modified by geranylgeranylation [104]. FBL2 lacking the CAAX motif was not modified by geranylgeranylation and lost the interaction with NS5A [104]. An F-box-truncated FBL2 mutant suppressed the replication of HCV as a dominant negative, whereas a mutant in the residues responsible for geranylgeranylation exhibited no suppressive effect [104]. The geranylgeranylated FBL2 is required for the replication of HCV but not for that of West Nile virus [104]. Furthermore, knockdown of FBL2 in the replicon cells induced suppression of HCV replication but not in cells expressing an siRNA-resistant FBL2 [104]. The F-box motif is generally essential for the formation of the ubiquitin ligase complex [105], suggesting that FBL2 regulates the ubiquitination of host or viral proteins through the interaction with NS5A. Another possibility is that FBL2 may retain the viral replication complex by interacting with NS5A (Figure 4).

CONCLUSION

The host machineries of lipid biosynthesis, protein folding and anchoring in the intracellular compartment may cooperate with HCV proteins to facilitate the replication of the viral genome. In addition, translation of the viral genome is also expected to utilise the host proteins to generate viral proteins. Other host factors such as cellular RNA helicase p68 and nucleolin were also reported to be involved in HCV RNA replication [106,107]. The primary concern of chronic hepatitis C is the development of hepatocellular carcinoma through liver steatosis and fibrosis. HCV proteins could potentiate the production of reactive oxygen species, which may activate STAT3 leading to carcinogenesis [101,108–111]. Among HCV proteins, only the core protein was shown to be involved in the induction of carcinogenesis [112–114]. Data on the replication of HCV cooperating with host proteins have been accumulated by using RNA replicon and cell culture systems. Further studies on the host proteins involved in viral replication and carcinogenesis are needed for the development of therapeutic measures for chronic hepatitis C.

ACKNOWLEDGMENTS

We gratefully thank H. Murase for her secretarial work. This work was supported partly by grants-in-aid from the Ministry of Health, Labor, and

Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; the 21st Century Center of Excellence Program and the Foundation for Biomedical Research and Innovation, Japan.

REFERENCES

- Moriishi K, Matsuura Y. Mechanisms of hepatitis C virus infection. *Antivir Chem Chemother* 2003; **14**: 285–297.
- Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis* 2000; **20**: 1–16.
- Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; **39**: 1147–1171.
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958–965.
- Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 1999; **285**: 110–113.
- Sakamoto H, Okamoto K, Aoki M, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. *Nat Chem Biol* 2005; **1**: 333–337.
- Ni ZJ, Wagman AS. Progress and development of small molecule HCV antivirals. *Curr Opin Drug Discov Devel* 2004; **7**: 446–459.
- Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. *J Biol Chem* 2004; **279**: 17508–17514.
- Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol Cell* 2005; **19**: 111–122.
- Okamoto T, Nishimura Y, Ichimura T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. *EMBO J* 2006; **25**: 5015–5025.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346–355.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975–982.
- Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci USA* 2005; **102**: 9294–9299.
- Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 2005; **11**: 791–796.

15. Lindenbach BD, Evans MJ, Syder AJ, *et al.* Complete replication of hepatitis C virus in cell culture. *Science* 2005; **309**: 623–626.
16. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. *J Virol* 1993; **67**: 4017–4026.
17. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. *J Virol* 1993; **67**: 2832–2843.
18. Hamill P, Jean F. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells. *Biochemistry* 2005; **44**: 6586–6596.
19. Egger D, Wolk B, Gosert R, *et al.* Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J Virol* 2002; **76**: 5974–5984.
20. Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. *Proc Natl Acad Sci USA* 2004; **101**: 13038–13043.
21. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. *Science* 2000; **290**: 1972–1974.
22. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. *EMBO J* 1996; **15**: 12–22.
23. Hamamoto I, Nishimura Y, Okamoto T, *et al.* Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J Virol* 2005; **79**: 13473–13482.
24. Tu H, Gao L, Shi ST, *et al.* Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. *Virology* 1999; **263**: 30–41.
25. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. *Nature* 1989; **337**: 476–478.
26. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. *Nature* 1989; **341**: 755–757.
27. Siekierka JJ, Staruch MJ, Hung SH, Sigal NH. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. *J Immunol* 1989; **143**: 1580–1583.
28. Rahfeld JU, Schierhorn A, Mann K, Fischer G. A novel peptidyl-prolyl cis/trans isomerase from *Escherichia coli*. *FEBS Lett* 1994; **343**: 65–69.
29. Schiene-Fischer C, Habazettl J, Schmid FX, Fischer G. The hsp70 chaperone DnaK is a secondary amide peptide bond cis-trans isomerase. *Nat Struct Biol* 2002; **9**: 419–424.
30. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* 1991; **66**: 807–815.
31. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. *Cell* 1993; **73**: 1067–1078.
32. Wiegers K, Rutter C, Schubert U, Grattinger M, Krausslich HG. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. *Virology* 1999; **257**: 261–274.
33. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5 α restricts HIV-1 infection in Old World monkeys. *Nature* 2004; **427**: 848–853.
34. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. *Nature* 2004; **430**: 569–573.
35. Caroni P, Rothenfluh A, McGlynn E, Schneider C. S-cyclophilin. New member of the cyclophilin family associated with the secretory pathway. *J Biol Chem* 1991; **266**: 10739–10742.
36. Spik G, Haendler B, Delmas O, *et al.* A novel secreted cyclophilin-like protein (SCYLP). *J Biol Chem* 1991; **266**: 10735–10738.
37. Allain F, Denys A, Spik G. Characterization of surface binding sites for cyclophilin B on a human tumor T-cell line. *J Biol Chem* 1994; **269**: 16537–16540.
38. Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV. Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. *Mol Endocrinol* 2000; **14**: 1175–1186.
39. Cohen E, Taraboulos A. Scrapie-like prion protein accumulates in aggregates of cyclosporin A-treated cells. *EMBO J* 2003; **22**: 404–417.
40. Ishii N, Watashi K, Hishiki T, *et al.* Diverse effects of cyclosporine on hepatitis C virus strain replication. *J Virol* 2006; **80**: 4510–4520.
41. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 2003; **38**: 1282–1288.
42. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshida M. Combined interferon α 2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. *J Gastroenterol* 2003; **38**: 567–572.
43. Lam E, Martin M, Wiederrecht G. Isolation of a cDNA encoding a novel human FK506-binding

- protein homolog containing leucine zipper and tetrapeptide repeat motifs. *Gene* 1995; **160**: 297–302.
44. Edlich F, Weiwad M, Erdmann F, et al. Bcl-2 regulator FKBP38 is activated by Ca²⁺/calmodulin. *EMBO J* 2005; **24**: 2688–2699.
 45. Edlich F, Weiwad M, Wildemann D, et al. The specific FKBP38 inhibitor N-(N',N'-dimethylcarboxamidomethyl)cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. *J Biol Chem* 2006; **281**: 14961–14970.
 46. Nielsen JV, Mitchelmore C, Pedersen KM, Kjaerulff KM, Finsen B, Jensen NA. Fkbp8: novel isoforms, genomic organization, and characterization of a forebrain promoter in transgenic mice. *Genomics* 2004; **83**: 181–192.
 47. Bulgakov OV, Eggenschwiler JT, Hong DH, Anderson KV, Li T. FKBP8 is a negative regulator of mouse sonic hedgehog signaling in neural tissues. *Development* 2004; **131**: 2149–2159.
 48. Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. *Cell* 1993; **75**: 1417–1430.
 49. Chang DT, Lopez A, von Kessler DP, et al. Products, genetic linkage and limb patterning activity of a murine hedgehog gene. *Development* 1994; **120**: 3339–3353.
 50. Briscoe J, Ericson J. Specification of neuronal fates in the ventral neural tube. *Curr Opin Neurobiol* 2001; **11**: 43–49.
 51. Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature* 1996; **383**: 407–413.
 52. Chen Y, Struhl G. Dual roles for patched in sequestering and transducing Hedgehog. *Cell* 1996; **87**: 553–563.
 53. Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the Hedgehog receptor. *Nature* 1996; **384**: 176–179.
 54. Price MA, Kalderon D. Proteolysis of cubitus interruptus in *Drosophila* requires phosphorylation by protein kinase A. *Development* 1999; **126**: 4331–4339.
 55. Ohlmeyer JT, Kalderon D. Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator. *Nature* 1998; **396**: 749–753.
 56. Wijgerde M, McMahon JA, Rule M, McMahon AP. A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. *Genes Dev* 2002; **16**: 2849–2864.
 57. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science* 1997; **277**: 1109–1113.
 58. Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. *Nat Cell Biol* 2003; **5**: 28–37.
 59. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL. Host cell factor requirement for hepatitis C virus enzyme maturation. *Proc Natl Acad Sci USA* 2001; **98**: 13931–13935.
 60. Naito T, Momose F, Kawaguchi A, Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. *J Virol* 2007; **81**: 10740–10749.
 61. Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. *J Biol Chem* 2002; **277**: 45306–45314.
 62. Burch AD, Weller SK. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. *J Virol* 2005; **79**: 10740–10749.
 63. Kampmueller KM, Miller DJ. The cellular chaperone heat shock protein 90 facilitates Flock House virus RNA replication in *Drosophila* cells. *J Virol* 2005; **79**: 6827–6837.
 64. Connor JH, McKenzie MO, Parks GD, Lyles DS. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. *Virology* 2007; **362**: 109–117.
 65. Hu J, Toft DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. *EMBO J* 1997; **16**: 59–68.
 66. Hu J, Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. *Proc Natl Acad Sci USA* 1996; **93**: 1060–1064.
 67. Geller R, Vignuzzi M, Andino R, Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. *Genes Dev* 2007; **21**: 195–205.
 68. Skehel PA, Martin KC, Kandel ER, Bartsch D. A VAMP-binding protein from *Aplysia* required for neurotransmitter release. *Science* 1995; **269**: 1580–1583.
 69. Nishimura Y, Hayashi M, Inada H, Tanaka T. Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. *Biochem Biophys Res Commun* 1999; **254**: 21–26.
 70. Skehel PA, Fabian-Fine R, Kandel ER. Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. *Proc Natl Acad Sci USA* 2000; **97**: 1101–1106.
 71. Soussan L, Burakov D, Daniels MP, et al. ERG30, a VAP-33-related protein, functions in protein trans-